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ABSTRACT
Introduction: When a young person grows up, they
evolve from an independent child to an empowered
adult. If an individual has a chronic condition, this
additional burden may hamper adequate development
and independence. Transition programmes for young
persons with chronic disorders aim to provide the
necessary skills for self-management and participation
in care. However, strong evidence on the effects of
these interventions is lacking. Therefore, as part of the
STEPSTONES project (Swedish Transition Effects
Project Supporting Teenagers with chrONic mEdical
conditionS), we propose a trial to assess the
effectiveness of a structured, person-centred transition
programme to empower adolescents with congenital
heart disease in the transition to adulthood.
Methods/design: STEPSTONES will use a hybrid
experimental design in which a randomised controlled
trial is embedded in a longitudinal, observational study.
It will be conducted in 4 paediatric cardiology centres
in Sweden. 2 centres will be allocated to the
randomised controlled trial group, assigning patients
randomly to the intervention group (n=63) or the
comparison group (n=63). The other 2 centres will
form the intervention-naïve control group (n=63). The
primary outcome is the level of patient empowerment,
as measured by the Gothenburg Young Persons
Empowerment Scale (GYPES).
Ethics and dissemination: The study has been
approved by the Regional Ethical Board of Gothenburg,
Sweden. Findings will be reported following the
CONSORT statement and disseminated at international
conferences and as published papers in peer-reviewed
journals.
Trial registration number: NCT02675361; pre-results.
BACKGROUND
In developed countries, 10–40% of the adoles-
cent population has a chronic disease with
childhood onset.1 As a result of improvements
in diagnostic techniques and treatments, sur-
vival has increased, and 90% of them now
reach adulthood.2 Growing up with a chronic
condition poses an extra burden on the indi-
vidual, over and above the challenges typically
related to adolescence. Management of the
transition from childhood to adulthood and
the shift from paediatric to adult care requires
special attention from healthcare profes-
sionals. The movement to adult care is known
as transfer, deﬁned as “an event or series of
events through which adolescents and young
adults with chronic physical and medical con-
ditions move their care from a pediatric to an
adult health care environment”.3 This transfer
should be preceded by a preparatory transi-
tional phase. In healthcare, transition can be
deﬁned as the “process by which adolescents
and young adults with chronic childhood ill-
nesses are prepared to take charge of their
lives and their health in adulthood”.3 To
improve and facilitate this process, transition
Strengths and limitations of this study
▪ This is a multicentre study that uses a novel
study design to test the effectiveness of a
person-centred transition programme.
▪ Although several guidelines have recommended
the implementation of transition interventions,
the evidence of these is still insufficient. The
study is expected to fill a gap in current transi-
tional care knowledge.
▪ Owing to the type of intervention, blinding of
participants is not possible.
▪ In order to have a long follow-up, transition
interventions are recommended to start before
the age of 16 years, which is not feasible in this
study.
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programmes have been developed.4 A well-designed tran-
sition programme is individually tailored, ﬂexible, and
age and developmentally appropriate.5 The goal of transi-
tion programmes is to support the person’s adjustment to
a new care culture, to provide the necessary tools for self-
care and to help satisfy medical, psychosocial and educa-
tional needs.6 Evidence on the effects of transition pro-
grammes is scant, the level of existing evidence is low and
the effectiveness of these interventions has yet to be
determined.7 This is due to the limited number of effect-
iveness studies; methodological issues (eg, contamination
of control groups has not been accounted for in prior
studies) and a short follow-up period of 12 months
maximum.7
Patient empowerment is an asset that relates to the
adolescents’ self-management and participation in care.8
Empowered adolescents can interact better with the
adult healthcare system, and are more independent and
more actively involved in decisions regarding their
health.9 10 However, patient empowerment has not been
a formal target in transition programmes so far. To
increase the level of empowerment, a person-centred
care (PCC) approach is important.11 This perspective
allows for a partnership between the adolescent and
healthcare providers in which the adolescent’s views
guide the intervention.12 Through this approach, it is
possible to share helpful resources and information with
the adolescents and give them the opportunity to
assume an active role in the decision-making process.11
Congenital heart disease (CHD) is a typical example of
a life-course disease and can therefore be considered a
chronic condition. CHD has a prevalence of 9.1 per 1000
newborns and represents 28% of all congenital defects.13
Around 90% of children born with CHD reach adult-
hood,2 and ∼6.2 in 1000 adults live with this condition.14
Although several centres have established a transition
programme for individuals with CHD,15 only one study
on the effectiveness of such a programme has been
undertaken so far. That study was conducted in Canada
and used a quasi-experimental design to test the effects
of a 1-hour intervention led by a nurse.16 Signiﬁcant
improvements in the level of knowledge and self-
management among patients were observed.16 In add-
ition, a comparative and a longitudinal study in Belgium
conﬁrmed the effectiveness of patient education.17 18
To address the gaps in evidence on the effectiveness of
transition programmes, we established the STEPSTONES
project (Swedish Transition Effects Project Supporting
Teenagers with chrONic mEdical conditionS). This
project aims at developing and evaluating the effective-
ness of transition programmes for young persons with
chronic childhood-onset conditions. Although the project
will encompass different chronic conditions, it will ﬁrst
study adolescents with CHD.
Objective and hypothesis
This article describes the protocol for a study to test the
effectiveness of a transition programme to empower
adolescents with CHD in the transition to adulthood
and the transfer to adult care. The main hypothesis is
that adolescents with CHD who receive a structured,
person-centred transition programme over a 2-year
period have a higher patient empowerment score than
adolescents receiving usual care.
This study is presented in accordance with the guide-
lines issued by SPIRIT for reporting of study protocols.19
METHODS/DESIGN
Study design and setting
A hybrid experimental design will be used, in which a ran-
domised controlled trial (RCT) is embedded in a longitu-
dinal, observational study. This will result in a three-arm
design (see ﬁgure 1). The study will be conducted in four
CHD centres in Sweden. Two of the centres are allocated
to the RCT, where participants are randomly assigned to
either the intervention group or the comparison group.
The other two centres are designated as the control
group and represent intervention-naïve centres.
This type of design allows for the investigation of the
effectiveness of the transition programme while also
taking into account potential contamination of the com-
parison group in the intervention centres.
Sample size estimation
Sample size calculation is based on the primary outcome
of patient empowerment. The target is an improved
patient empowerment score of 5.25 points on a scale
from 15 to 75 (ie, 0.5 SD). For two-sided tests with
α=0.05 and power=80%, 63 patients are needed in each
arm of the RCT. In order to compensate for a potential
10% dropout rate, we will recruit 70 patients in each
arm of the RCT. An additional 70 patients will be
recruited in the centres of the control group. Among
the four centres, a total of 210 patients will be enrolled
(see ﬁgure 1).
Participants and recruitment
Eligible participants are (1) adolescents with CHD,
deﬁned as “a gross structural abnormality of the heart or
the intrathoracic great vessels that is actually or poten-
tially of functional signiﬁcance”;20 (2) age 16 years; (3)
Swedish speaking and (4) literate.
Patients are excluded if they do not have the physical
or cognitive capacity to complete the questionnaires, or
have acquired heart conditions or heart transplantation.
Parents of the adolescents will also be asked to partici-
pate. All eligible participants are recruited by a transi-
tion coordinator (TC) or a data collection ofﬁcer
(DCO).
Randomisation
Using a web-based system, a stratiﬁed block randomisa-
tion with a random variable block size will assign
patients of the RCT centres to the intervention group or
the comparison group (1:1).21 Block randomisation
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ensures that the TCs in the two centres have a relatively
continuous exposure to the intervention over time,
which allows them to keep their skills up to date and to
ensure the ﬁdelity of the intervention. The fact that the
block sizes vary randomly minimises the possibility that
the TCs could predict group assignments.
Stratiﬁcation is made by centre and disease complex-
ity. The stratiﬁcation for centre ensures that the two
centres have an equal number of intervention patients.
Stratiﬁcation by disease complexity (mild; moderate;
complex)22 is important to avoid over-representation of
those people with, for example, complex CHD in one or
the other group due to failing randomisation.
Overall, this approach decreases the within-centres
variability and reduces the risk for bias and confound-
ing.21 The TCs are responsible for accessing the ran-
domisation system in order to determine patient
allocation.
Intervention
Transition programme (intervention group)
This study implements a multicomponent intervention,
adapted from a brief transition programme developed
by Hilderson et al.23 Adaptation of the programme fol-
lowed the intervention mapping process.24 Intervention
mapping is a thorough method used to build compre-
hensive programmes for health promotion and consists
of six consecutive steps: (1) assessment of the needs of
the target population; (2) deﬁning programme objec-
tives by specifying performance and change objectives;
(3) determining theory-based intervention methods and
practical strategies; (4) designing and producing the
intervention programme; (5) adoption and implementa-
tion of the intervention; and (6) developing and execut-
ing a plan for evaluation.24 Applying the intervention
mapping method in this study ensures that the
intervention is well-grounded and includes the necessary
components to target the programme objectives. A
detailed description of each of the steps will be given in
a related article.
The transition programme includes eight key compo-
nents: (1) a TC; (2) a written person-centred transition
plan; (3) provision of information and education about
the condition, treatment and health behaviours; (4)
availability by telephone and email; (5) information
about and contact with the Grown-Up Congenital Heart
Disease (GUCH) clinic; (6) guidance of parents; (7)
meeting with peers; and (8) the actual transfer to the
GUCH clinic.
These components are implemented in ﬁve steps: (1)
a ﬁrst patient visit with the TC; (2) a second outpatient
visit with the TC; (3) information day for adolescents
and their parents; (4) a third outpatient visit with the
TC; and (5) actual transfer to the GUCH clinic. The
TCs are specialised nurses at the outpatient clinic of
paediatric cardiology who have received speciﬁc training
in performing this intervention.
Throughout the intervention, the TCs employ a PCC
approach. PCC implies that participants are active
agents in their care and decision-making process.12
Ekman et al12 proposes that PCC can be implemented in
three stages. First, initiating the partnership by allowing
the patients to tell their story (patient narratives). This
allows for the patients’ views to be at the centre of care.
Second, developing the partnership through constant
communication between the patient and healthcare pro-
viders. This is accomplished by sharing experiences and
building a common understanding of the care plan.
Third, safeguarding the partnership by documenting
the decisions made and the preferences of the patients.
The content of the visits is individualised, age and
developmentally adapted, and it is documented in the
Figure 1 Overview of the study design and implementation steps.
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individualised transfer plan. The TCs, together with the
adolescent, are in charge of determining which topics
are important to discuss, in establishing goals related to
patient empowerment and in assessing the need for
referral to other services.
Usual care (intervention, control and comparison group)
All adolescents who participate in the study receive
usual care, irrespective of whether in the intervention,
comparison or control group. Usual care includes visits
to an outpatient paediatric cardiology clinic where they
meet a nurse and a paediatric cardiologist. Disease com-
plexity determines the frequency of the visits. None of
the participating centres have a TC as a part of usual
care and there is no documentation of transition plans.
It is common practice in Sweden that patients are trans-
ferred to adult care around the age of 18 years.
Since usual care can vary across clinics and over time,
an assessment of transition-related practices will be
carried out in all the centres at the beginning of the
intervention and at the end of the study. This assessment
will comprise three elements: (1) a structured survey
called CHAT (Congenital Heart Adolescent and
Transition; on ﬁle); (2) interviews with healthcare pro-
fessionals who are involved in the care for adolescents
with CHD in the participating centres and (3) observa-
tions of the routine during the clinic visits.
Blinding
Owing to the nature of the intervention and the study
design, it is not possible to blind the participants, TCs or
DCOs. However, the TCs and DCOs in charge of carry-
ing out the intervention and data collection are not
involved in the preparation of the intervention design or
in the statistical analyses.
To avoid cross-contamination between the comparison
and the intervention group within the RCT centres, TCs
are not involved in the delivery of care of the com-
parison group and other healthcare professionals in the
participating centres will not be informed of the inter-
vention components. DCOs in the control group do not
participate in discussions of the intervention.
Intervention fidelity
To ensure that the transition programme is implemen-
ted according to the developed intervention, the TCs
are selected based on their experience of working with
children and adolescents with CHD. In preparation for
this study, they received a speciﬁcally designed 4 days
training programme, addressing adolescents’ health and
development; communicating with and interviewing
young persons; patient education; PCC; and the detec-
tion of and screening for risk behaviours. Training is
given by experts in the aforementioned ﬁelds and fea-
tures different pedagogical approaches, for example,
group discussions, case assessments and role play. In
addition, the TCs were asked to read two textbooks on
adolescent health and PCC.
Standard operating procedures (SOPs) for each group
of the study were developed in order to ensure consist-
ency throughout the study. These SOPs included: ethical
approval; study preparation; study administration; partici-
pants recruitment and survey completion; intervention
characteristics; usual care; data storage, entry and secur-
ity; study progress; and publication policy.
Intervention ﬁdelity is monitored as part of the process
evaluation. The Medical Research Council (MRC) guid-
ance on process evaluation of complex interventions is
applied,25 and both quantitative and qualitative methods
will be used. In the quantitative assessment, we investi-
gate the acceptability, adherence/ﬁdelity and attrition,
as well as potential safety issues. These data are collected
using three assessment forms (enrolment/follow-up
form, adverse events (AEs) report and intervention
implementation form) ﬁlled out by the TCs during the
intervention period. The qualitative assessment will
obtain information about the experiences of and imple-
mentation by the TCs and will provide insights into the
mechanisms of impact based on the experiences of
patients and their parents. The process evaluation will
be undertaken as a separate study conducted in parallel
with this effectiveness study.
Follow-up period and data collection
During the 2-year follow-up period, outcome measure-
ments are assessed on three different occasions: T0,
baseline when the participants are 16 years old; T1,
midterm when the participants are 17 years; and T2,
ﬁnal data collection when the participants have been
transferred to adult care and are ∼18.5–19 years old (see
ﬁgure 1).
Participants from the intervention group will be
mailed the set of questionnaires 1 month before the out-
patient clinic visit. If the questionnaires have not been
received by the time of the visit, they will have the
opportunity to complete them while waiting for their
appointment. Patients from the control and comparison
groups may not have a scheduled outpatient visit.
Therefore, data collection in these groups is completely
undertaken by post when the participants are 16 (T0),
17 (T1) and 18.5 years old (T2).
To minimise non-response in the comparison and
control groups, a modiﬁed Dillman procedure will be
used.26 Two weeks after the documents are sent, non-
responders will receive a ﬁrst personalised reminder in
the form of a text message. If after 4 weeks the question-
naires have not been received, a reminder letter and a
new set of questionnaires is sent. After 6 weeks, persistent
non-responders are contacted by telephone and asked
whether they received the questionnaires, if the mailing
address is correct, if they want a new set of questionnaires
and if they want to continue participating in the study.
After 8 weeks, a last reminder is sent to those who agree
to participate in the study during the telephone call.
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Outcome measurements
A background information questionnaire is included,
comprising sociodemographic variables such as sex, age,
educational level, size of community, place of birth,
number of siblings, birth order, living situation, other
health conditions and medication (obtained from self-
report and medical ﬁle).
Standardised questionnaires are used to assess primary
and secondary outcomes. Table 1 presents an overview
of the characteristics and psychometric properties of the
questionnaires used.
Primary outcome measures
The primary outcome is patient empowerment, deﬁned
as “an enabling process or outcome arising from com-
munication with the healthcare professional and a
mutual sharing of resources over information relating to
illness, which enhances the patient’s feelings of control,
self-efﬁcacy, coping abilities and ability to achieve
change over their condition”.9 Empowerment includes
ﬁve dimensions: (1) identity; (2) knowledge and under-
standing; (3) personal control; (4) decision making; and
(5) enabling others.9
Since no questionnaire to measure the level of
empowerment in young persons with chronic conditions
exists, we developed the Gothenburg Young Persons
Empowerment Scale-Congenital Heart Disease module
(GYPES-CHD). The scale has 15 items, 3 items for each of
the aforementioned dimensions. Each item is answered
on a ﬁve-point Likert scale: strongly disagree; disagree;
neither agree nor disagree; agree and strongly agree. A
total score is calculated by summing the item scores. The
total score ranges from 15 to 75 points, with a higher
score reﬂecting a higher level of patient empowerment.
Face validity was conﬁrmed after cognitive interviews
with six young persons with CHD. The psychometric
properties of this scale were examined in a cross-
sectional study in 205 young persons with CHD. Internal
consistency of the items was conﬁrmed with a
Cronbach’s α of 0.821. No ﬂoor or ceiling effect in
scoring was observed. A complete description of the psy-
chometric evaluation of GYPES will be provided in
another article.
Secondary outcomes measures
We will measure six secondary outcomes in the adoles-
cents: transition readiness, health behaviours, knowledge
about CHD, healthcare usage, quality of life and patient-
reported health. In the parents, we will measure transi-
tion readiness (proxy) and parental uncertainty towards
transition.
Transition readiness
Transition readiness is deﬁned as the “adolescent’s readi-
ness to assume complete responsibility for their health-
care and their readiness to transfer to adult medical
care”.27 Transition readiness is evaluated using
the Readiness for Transition Questionnaire (RTQ),
adolescent and parent versions. These questionnaires
examine two aspects. First, the overall transition readi-
ness is assessed, using two items ranging from 1 to 4.
The sum of these two items results in a score ranging
from 2 to 8. Second, the frequency of adolescent respon-
sibility and parental involvement are reported in 10 dif-
ferent health behaviours, on a ﬁve-point Likert scale.
Each variable results in a total score ranging from 10 to
40, and higher scores indicate higher adolescent respon-
sibility or parental involvement, respectively.
Knowledge about CHD
Adolescents’ knowledge about their CHD is assessed
with the Knowledge Scale for adults with Congenital
Malformed Hearts (KnoCoMH).28 This instrument eval-
uates the level of knowledge within four domains:
disease and its treatment; complications prevention;
physical activity; and reproductive issues.28 The question-
naire includes 19 items and scores are calculated by
dichotomising answers as correct or incorrect. Access to
the medical ﬁles is needed in order to conﬁrm the
answers in some of the items. For participants for whom
medical treatment or endocarditis prophylaxis is not
recommended, the domains are excluded.
Health behaviours
Health behaviours are measured with the Health
Behavior Scale-CHD. Health behaviours are ‘activities a
person undertakes to maintain or improve health and
prevent diseases’.30 This scale assesses alcohol consump-
tion, tobacco use, dental care and physical activity. The
scale has 15 items that help to calculate three summary
risk scores: substance use (score 0–100), dental hygiene
(score 0–100) and total health risk score (score 0–100).
Higher risk scores represent unhealthier behaviours.
Patient-reported health
Patient-reported health is assessed by the generic and
cardiac modules of the Pediatric Quality of Life inven-
tory 4.0 (PedsQL 4.0), as well as the EuroQoL 5 dimen-
sions 3 levels (EQ-5D-3L). The PedsQL 4.0 provides
information on health status in relation to psychosocial
and physical health.32 The generic module consists of 23
items that cover four dimensions: physical; emotional;
social functioning and school functioning. Items are
answered by using a ﬁve-point Likert scale: never, almost
never, sometimes, often and always. For each dimension,
a scale score can be calculated, which ranges from 0 to
100. Further, a physical health summary score, a psycho-
social health summary score and a total score can be
calculated.
The cardiac module contains 27 items that cover six
dimensions: symptoms; treatment; perceived physical
appearance; treatment anxiety; cognitive problems and
communication. Each item is answered using a ﬁve-point
Likert scale (never, almost never, sometimes, often and
always). As in the generic version, scores are
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Table 1 Psychometric properties of the questionnaires used in STEPSTONES-ConHD
Variable Subject Measurements Items Validity Reliability Responsiveness Interpretation
Primary outcome
Patient
empowerment
AD GYPES 15 Construct validity supported an
adequate model fit of a five factor
solution (df: 80; χ2: 154–948,
p<0.0001; CFI: 0.916; RMSEA: 0.068;
SRMR: 0.069) (data on file)
Face validity confirmed in young
persons with chronic conditions (data
on file)
Internal consistency
confirmed in young
persons with CHD,
α=0.819 (data on file)
Floor scores: 0%;
ceiling scores: 1.5%
(data on file)
Score from 15 to
75. Higher score
reflects a higher
level of patient
empowerment
Secondary outcomes
Transition
readiness
AD RTQ adolescent
version
26 Validity based on relationships with
other variables confirmed in young
persons with kidney transplant,27 p.91–
92
Internal consistency
confirmed in young
persons with kidney
transplant; α values
over 0.7027
NR Scores from 10 to
40. Higher scores
denote increased
adolescent or
caregiver
responsibility.
PA RTQ parent
version
Construct validity reported for parents
of young persons with kidney
transplant,27 p.91–92
Reliability reported for
parents of young
persons with kidney
transplant; α values
over 0.70,27 p.90
NR
Knowledge on
ConHD
AD KnoCoMH 19 Validity was confirmed in adults with
CHD in relation to discrimination ability,
the relationship of the items and the
construct of interest,28 p.232–234
KnoCoMH is based on the Leuven
Knowledge Scale which has been
validated in young persons with
CHD,29 p.79–80
Internal consistency
and test–retest reliability
confirmed,28 p.232–234
NR Scores are
calculated by
dichotomising the
answers (correct/
incorrect) for each
domain
Health
behaviours
AD HBS-CHD 15* Item content validity, scale content
validity index and validity based on
relationships to other variables
confirmed in adolescents with CHD,30
p.548
Stability not confirmed29 Confirmed in
adolescents with CHD
by Guyatt’s
Responsiveness
Index,30 p.551
Substance use,
dental hygiene and
total health risk
score from 0 to
100. Physical
exercise score
from 0 to ∞
Patient-reported
health
AD PedsQL generic
module
23 Convergent validity, measurement
invariance and factor structure
confirmed in paediatric populations,
31 p.336–337
32 p.1507–1510
Test–retest reliability
and internal consistency
show α values over
0.70 in paediatric
populations,32 p.1507
31 p.333–335
Minimal clinically
important difference
reported for young
people with CHD was
6.0 for the total
score.33
Scores from 0 to
100. Higher scores
indicate a better
perceived health
status.
Continued
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Table 1 Continued
Variable Subject Measurements Items Validity Reliability Responsiveness Interpretation
PedsQL cardiac
module
27 Convergent validity was confirmed,34
p.215
Internal consistency for
majority of scales
exceeded α values of
0.70,34 p.214
Minimal clinically
important differences
reported for young
people with CHD
ranged from 7.6 for
symptoms to 12.6 for
communication.33
Scores from 0 to
100. Higher scores
indicate lower
problems.
EQ-5D-3L 5 Convergent and discriminative validity
confirmed in patients with
cardiovascular disease,35 p.6
Test–retest reliability
confirmed in
cardiovascular
patients,35 p.6
Confirmed in patients
with cardiovascular
disease,35 p.6
Scores from 1 (no
problems) to 3
(extreme
problems) on five
dimensions
Scores from 0
(worst imaginable
health state) to
100 (best
imaginable health
state)
Quality of life AD LAS 1 Validity based on relationship with
Satisfaction with Life Scale found to be
highly correlated (ρ=0.52). Test content
confirmed in adults with CHD (100% of
patients understood the wording and
format)36
Validity has been evaluated in
adolescents with CHD.37 38
Test–retest reliability
confirmed in adults with
CHD (ICC=0.65),36
Confirmed in adults
with CHD (floor
scores=0%, ceiling
scores=2.7%)36
Score is from 100
(best imaginable
health status) to 0
(worst imaginable
health status).
Healthcare
usage
AD Healthcare
usage
questionnaire
11 NA NA NA NA
Parental
uncertainty
towards transfer
to adult care
PA LAS 1 Face validity confirmed in parents of
young persons with chronic conditions
(data on file).
Test content confirmed in parents of
young persons with CHD (100% of
patients understood the wording and
format).
NR Floor scores: 7.8%;
ceiling scores: 4.8%
(data on file)
Score is from 0
(very uncertain
about the transfer
to adult care) to
100 (not uncertain
about the transfer
of care).
AD, adolescents; CFI, comparative fit index; CHD, congenital heart disease; EQ-5D-3L, EuroQoL 5 dimensions 3 levels; GYPES, Gothenburg Young Persons Empowerment Scale; HBS-CHD,
Health Behavior Scale-Congenital Heart Disease; ICC, intra-class correlation; KnoCoMH, Knowledge Scale for Adults with Congenitally Malformed Hearts; LAS, linear analogue scale;
NA, not applicable; NR, not reported; PA, parents; PedsQL, Pediatric Quality of Life Inventory 4.0; RMSEA, root mean square error of approximation; RTQ, Readiness for Transition
Questionnaire; SRMR, standardised root mean square residual; STEPSTONES, Swedish Transition Effects Project Supporting Teenagers with chrONic mEdical conditionS.
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transformed on a scale from 0 to 100, and then a mean
subscale core is calculated.34
The EQ-5D-3L comprises a descriptive system and a
visual analogue scale (VAS). The descriptive system has
ﬁve dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression) with three
response categories per dimension.39 The participants
are asked to indicate which statement is most suitable in
relation to their health status. The VAS measures the
participants’ self-rated health on a scale with the end
points ‘best imaginable health possible’ (=100) and
‘worst imaginable health state’ (=0). The descriptive
system allows for the determination of a ﬁve-digit health
state that combines the level of perceived problems in
each dimension (level 1: indicating no problem, level 2:
indicating some problems and level 3: indicating
extreme problems). Information obtained from the
descriptive system can be converted to a single summary
index by assigning values to each level of every
dimension.
Quality of life
Quality of life is deﬁned as “the overall degree of life sat-
isfaction that is positively or negatively inﬂuenced by
individuals’ perception of certain aspects of life import-
ant to them, including matters both related and unre-
lated to health”.40 This variable is measured using a
10 cm linear analogue scale (LAS),36 where the partici-
pants indicate in the scale how they judge their current
quality of life. The scale looks similar to the VAS of the
EQ-5D, but has the end points ‘best imaginable quality
of life’ (=100) and ‘worst imaginable quality of life’ (=0).
Healthcare usage
Healthcare usage within the preceding 6 months is mea-
sured in relation to their CHD and other possible condi-
tions. The measurement consists of six dimensions:
hospital stay; healthcare contact; specialised care; emer-
gency care; school absence and follow-up unit after
transfer to adult care. This assessment was developed to
be used in the APPROACH-IS project.41 After the trans-
fer to adult care, we will assess the proportion of patients
who are in follow-up in a GUCH unit, both in the inter-
vention and control arms.
Parental uncertainty
Parental uncertainty is understood as the degree of cer-
tainty/uncertainty the parents have in relation to their chil-
dren being transferred to adult care. This outcome is
measured through LAS with the end points ‘extremely
uncertain’ (=100) and ‘not uncertain at all’ (=0). This LAS
has been developed for the purpose of the present study.
In addition to the primary and secondary end points,
we will calculate a composite end point. We will do so
because the transition programme is a complex inter-
vention that may have varying effects on different out-
comes. Prior studies on the impact of transition
programmes showed that the intervention has impacted
on transition readiness,16 patient knowledge,16 quality of
life42 and psychosocial health.42 Therefore, each patient
will be categorised as improved or not. Patients will be
classiﬁed as improved if they have an improvement in
empowerment, transition readiness, knowledge, quality
of life or psychosocial health of 0.5 SDs compared with
their baseline measurement.
Data management
Data are entered into a web-based system by the TC and
the DCO. Those with access to the system are the TC,
DCO, project coordinator and principal investigator,
each of whom has a personal login. All data are checked
for completeness and the quality of the data is moni-
tored at least twice a year by the members of the
research group. This process is carried out by verifying
records with the raw data and checking frequency distri-
butions to identify responses outside of the given
possibilities.
Statistical analyses plan
The primary analyses will be performed following the
intention-to-treat principle which helps to avoid biases in
the comparisons between groups. The primary end
point (level of empowerment) will be analysed using
Fisher’s non-parametric permutation test unadjusted
between the two groups. Complementary between-group
analyses will be made using analysis of covariance
adjusted for baseline variables that differ signiﬁcantly
between groups and for each centre.
All analyses will be predeﬁned in a comprehensive stat-
istical analysis plan before data lock. The level of signiﬁ-
cance will be at p≤0.05. Two-sided tests will be used.
Trial duration
Patient recruitment began in July 2016 and is planned
to ﬁnish in December 2017. Once recruited, patients are
followed up until they are transferred to GUCH. Data
collection is expected to be ﬁnished by December 2019.
After the data set is locked, analysis and dissemination
of results will begin.
Ethical considerations
Before inclusion in the study, the TCs and DCOs will
seek written informed consent from the adolescents and
their parents after they have received written and oral
information about the study. Participants have the right
to withdraw at any point throughout the study. The prin-
ciples established in the Declaration of Helsinki will be
followed during the entire duration of the study.43
To ensure conﬁdentiality, personal data are coded.
Participant and study-related information is stored in
locked cabinets and digital documents are password-
protected.
Follow-up on AEs
All AEs must be reported to the principal investigator
and project coordinator within a week. In case of a
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serious AE, the report must be made immediately.
Appropriate measures will be undertaken in every AE in
order to ensure patient safety.
Dissemination
The results of this study will be submitted to peer-
reviewed journals for publication following the
CONSORT statement.44 Abstracts for poster or oral pre-
sentations will be submitted to international confer-
ences. Authorship is granted to a collaborator from
every participating centre and members of the research
group fulﬁlling the criteria of authorship.45 46 If pos-
sible, we will include ‘on behalf of STEPSTONES-CHD’
in the list of authors. After completion of the study, the
data set will be available on formal request.
DISCUSSION
Previous studies have tried to determine the effective-
ness of transition programmes. However, owing to
several methodological limitations, the true effect of
these interventions is still uncertain.7 Therefore, we will
conduct a study that assesses the effectiveness of a struc-
tured, person-centred transition programme to empower
adolescents with CHD in the transition to adulthood.
Through the implementation of the proposed transition
programme, we expect an increase in the level of
empowerment. A high level of empowerment can help
the adolescent navigate through the adult care system,
participate in care planning, and increase self-
management and decision-making skills.8
The intervention in this trial was designed and initially
evaluated by Hilderson et al23 42 in Belgium. Therefore, it
was important to determine if the intervention compo-
nents were suitable in the Swedish setting. To accomplish
this, ﬁve preparatory studies were carried out (four quali-
tative, one quantitative study). The qualitative studies
included individual and focus group interviews with
young persons with CHD and their parents.47 48 These
studies provided an overview of the current transition
practices in Sweden and the needs of this population
before the transfer to adult care. The quantitative study
was a cross-sectional study including 205 young persons
with CHD, and served as a pilot-test for our primary
outcome measurement. Furthermore, the intervention
was discussed with a panel of international experts with
experience in transition research in adolescents with
chronic conditions and patient representatives.
The preparatory studies and the discussion with the
panel of international experts improved the quality,
feasibility and acceptability of the intervention. This
interdisciplinary and comprehensive approach increases
the chance of producing a high-quality intervention with
positive results.49
This study has several strengths, because we explicitly
take limitations of prior studies into account. First, we
employ an RCT which is the gold standard for the
assessment of the effectiveness of interventions and pro-
vides the highest level of evidence. The stratiﬁed block
randomisation that we undertake ensures that the inter-
vention and comparison groups are balanced and that
potential confounding factors, such as complexity of the
disease or centre characteristics, are equally distributed
and therefore minimise the risk of biasing the results.
Second, the proposed hybrid experimental design
allows us to account for potential contamination of the
control group. Indeed, the three arms allow perform-
ance of direct comparison between the intervention
and comparison group while enabling a comparison of
ﬁndings with those obtained in intervention-naive
centres.
Third, patient empowerment is used as the primary
outcome. Empowerment is argued to be important for
the development and application of skills to promote
behavioural changes in the adolescents.10 Admittedly,
empowerment can be seen both as a process and an
outcome.10 However, being an intermediate outcome,
empowerment can be argued to be proximal to the
intervention, whereas continuing cardiac care, reduced
morbidity or mortality are probably the ultimate, but
more distal outcomes.
Fourth, the PCC approach that is used throughout the
transition programme is an important asset in the
process of empowering patients.11 Providing transitional
care from a person-centred perspective is novel and has
not been evaluated before in this age group.
Fifth, we follow-up the patients for more than 2 years.
While doing so, we substantially expand the follow-up
period of 12 months as used in prior studies.7
Sixth, since usual care may vary across centres and
over time, we carry out a formal usual care assessment.
Such a usual care assessment is important to draw ﬁrm
conclusions, and yet this is seldom performed in clinical
trials.50
Irrespective of these strengths, we anticipate some lim-
itations as well. First, we are not able to blind the partici-
pants or the healthcare team that will perform the
intervention. To minimise a potential impact, neither
the therapeutic team nor the TCs participate in the data
analysis. Second, there is a possibility of a relatively long
period of recruitment for participants which can require
extending the trial period and delaying data analysis.
Third, transition interventions have been advised to start
early on, for example, between 10 and 12 years of age,
and have a long follow-up.51 Furthermore, a long
follow-up allows continuity of care to be measured in
this population and provides insight into the effects of
the transition programme over this parameter. Although
we recognise the importance of starting early, it would
have jeopardised the feasibility of the study, because it
would have taken almost a decade to ﬁnish recruitment
and follow-up until the age of 18 years. Nonetheless, it
could be possible to later on assess loss of follow-up in a
separate study.
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CONCLUSION
This article described the study protocol for a study to
assess the effectiveness of a structured, person-centred
transition programme for young persons with CHD.
This study accounts for limitations of previous research
and addresses an existing gap in the evidence of transi-
tional care. It is hoped that the ﬁndings will provide
strong evidence of the effectiveness of this intervention
in young people with CHD. If successful, this transition
programme could potentially be implemented as part of
routine care provided to young persons with CHD, and
transfer to other chronic conditions can be explored.
Trial status
Status of the trial at the time of submission: patient
recruitment.
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